Method. We reviewed international individual case safety reports of suspected adverse drug reactions (ADRs) from the World Health Organization drug safety database, VigiBase, which contains over 4.5 million records from more than 90 countries (as of March 2009). 4 Although the data are heterogeneous, at least with respect to origin (country as well as reporter of the ADR) and content (eg, quality and assessment of causality), they have been used to highlight and support emerging drug safety issues. [5] [6] [7] We analyzed all cases of SCD during SGA treatment that were identified in VigiBase on January 10, 2008. Obvious duplicates and suicides were excluded. Drugs known to prolong the QT interval were defined as drugs generally accepted by the QT Drug Lists Advisory Board of the Arizona Center for Education and Research on Therapeutics to carry a risk, a possible risk, or a conditional risk of causing torsades de pointes. 8 A disproportionality measure, the Information Component (IC), was used to identify if SCD was excessively reported for the various SGAs relative to the overall reporting rate in VigiBase. 9, 10 Results. In VigiBase, a total of 462 unique reports of SCD during SGA treatment, from 17 countries, were identified (Table 1) . Clozapine was the suspected agent in most reports. Notably, the reports often concerned relatively young patients, the median age being 43 years. In 80% of the reports the SGA was the sole suspect for the reaction, and in 66% of all reports no additional drug known to prolong the QT interval was reported. The duration of treatment was 3 months or less in 43% of the reports. SCD was reported disproportionately more often for SGAs compared to the overall reporting in VigiBase, although the IC value is uncertain for the SGAs with very few reports.
Rigorous monitoring for agranulocytosis during clozapine treatment could lead to increased reporting of other ADRs as well. This might have contributed to the large proportion of reports with sudden cardiac deaths with clozapine as the suspected agent. Other reporting biases, including variable differential underreporting of suspected ADRs, 11 probably exist for these data, and Letters to the editor comparisons between drugs should therefore be considered with great caution.
In conclusion, these data suggest that SCD in SGA users is likely to be an international problem and may occur early in treatment and in younger patients. More studies are urgently needed to investigate the association further.
